SRA/CD204 attenuates immunostimulatory activity of TLR4-engaged DCs in vivo. (A) Increased IFN-γ production by OVA-specific CTLs from SRA^−/− DC-immunized mice. WT mice (n = 3) were immunized with OVA-pulsed DCs activated with or without LPS. Splenocytes were harvested and restimulated with OVA_257-264 and subjected to an ELISPOT assay (*P < .001, LPS-treated SRA^−/− DC vs LPS-treated WT DC). (B) Improved OVA-specific cytolytic activity in SRA^−/− DC-immunized mice. After vaccinations with WT or SRA^−/− DCs, mice were inoculated intravenously with 5 × 10⁶ OVA_257-264-pulsed, CFSE^high splenocytes and nonpulsed, CFSE^low population. Lymph node cells were analyzed by FACS after 12 hours. Data represent an example of the FACS data from 3 mice per experimental group. (C) Increased tumor-lytic activity of T-effector cell from SRA^−/− DC-immunized WT mice. Splenocytes from WT or SRA^−/− DC-immunized mice were restimulated with OVA_257-264, and subjected to chromium release assays using OVA_257-264-pulsed B16 cells as targets. Data shown as mean plus or minus SD are representative of 2 experiments.